Bone mineral density (BMD) is a heritable complex trait used in the clinical diagnosis of osteoporosis and the assessment of fracture risk. We performed meta-analysis of five genome-wide association studies of femoral neck and lumbar spine BMD in 19,195 subjects of Northern European descent. We identified 20 BMD loci that reached genome-wide significance (GWS; P < 5 × 10 −8 ), of which 13 map to regions not previously associated with this trait: 1p31.3 (GPR177), 2p21 (SPTBN1), 3p22 (CTNNB1), 4q21.1 (MEPE), 5q14 (MEF2C), 7p14 (STARD3NL), 7q21.3 (FLJ42280), 11p11.2 (LRP4, ARHGAP1, F2), 11p14.1  (DCDC5), 11p15 (SOX6), 16q24 (FOXL1), 17q21 (HDAC5) and 17q12 (CRHR1) . The meta-analysis also confirmed at GWS level seven known BMD loci on 1p36 (ZBTB40), 6q25 (ESR1), 8q24 (TNFRSF11B), 11q13.4 (LRP5), 12q13 (SP7), 13q14 (TNFSF11) and 18q21 (TNFRSF11A). The many SNPs associated with BMD map to genes in signaling pathways with relevance to bone metabolism and highlight the complex genetic architecture that underlies osteoporosis and variation in BMD.
Osteoporosis is characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to loss of bone strength and increased risk of fracture. Osteoporosis increases in incidence with age and is an important health threat to hundreds of millions of elderly individuals worldwide. Linkage analysis in monogenic bone disorders such as osteoporosis-pseudoglioma syndrome, sclerosteosis, high-bone-mass syndrome and Paget's disease have yielded important advances in recent years and highlighted the importance of the Wnt signaling 1 and RANK-RANKL-Opg pathways in the regulation of bone mass and bone turnover 2 . However, linkage studies for the common form of osteoporosis have had limited success 3 . As with other complex diseases, most of the candidate gene association studies in osteoporosis have produced conflicting results with limited replication 4 , mostly owing to small sample sizes 5 . However, large studies of major candidate gene polymorphisms within the sufficiently powered setting of the GENOMOS consortium have been successful in obtaining consistent evidence of association between some genetic variants, BMD and fracture risk [6] [7] [8] [9] [10] . Concurrently, genome-wide association studies (GWAS), which perform a hypothesis-free search for genetic determinants 11 , have already identified ten loci that are associated at a GWS level with BMD 12, 13 . Four of these loci encode members of the Wnt and RANK-RANKL-Opg signaling pathways, highlighting their role in monogenic forms of osteoporosis as well as in the common form.
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies 1 2 0 0 volume 41 | number 11 | november 2009 Nature GeNetics A r t i c l e s BMD is used in clinical practice for the diagnosis of osteoporosis and in the assessment of fracture risk 14 . BMD is usually measured at the hip (femoral neck) and lumbar spine, which are common sites of fracture. However, BMD measurements at different skeletal sites are predictive of fracture in general because of their high correlation (r 2 ~0.60) 15 . From a genetic perspective, BMD at both spine and hip is a complex but highly heritable trait (h 2 ~0.60-0.80) 16 . As shown for human height [17] [18] [19] , dozens and possibly hundreds of loci with small effects can be expected to influence variation in BMD. Detection and reliable documentation of these loci with weak effects require studies with comprehensive coverage of the genome and very large sample sizes. Here we report the findings of a large-scale meta-analysis of 19, 195 adults from five GWAS that examined BMD of the lumbar spine (LS-BMD) and the femoral neck (FN-BMD) within the setting of the Genetic Factors for Osteoporosis (GEFOS) Consortium.
RESULTS

Samples, genotyping and analysis of genome-wide scans
The five study populations were from the Rotterdam Study (RS, n = 4,987), Erasmus Rucphen Family Study (ERF, n = 1,228), Twins UK Study (TUK, n = 2,734), deCODE Genetics Study (dCG, n = 6,743) and Framingham Osteoporosis Study (FOS, n = 3,503). The ages of participants ranged from 18 to 96 years. All studies had a majority of women (range 57-88%) in their samples, with TUK including women only. Additional characteristics of the study populations and subject exclusion criteria are presented in Supplementary Tables 1 and 2, respectively.
Identification of BMD loci
Association results (corrected by the genomic control method 20 ) of all HapMap CEU imputed SNPs that passed quality control criteria in each study ( Supplementary Table 3 ) were meta-analyzed using METAL 21 . We declared results genome-wide significant at α = 5 × 10 −8 after adjusting for all common variant tests in the human genome 22, 23 . We investigated whether there was an excess of significant associations by comparing the test statistics to those expected under the null distribution using interquantile-quantile plots (corrected for overall meta-analysis genomic control λ LS-BMD = 1.09 and λ FN-BMD = 1.08). We found strong (and not early) deviation of the observed statistics from the null distribution for both BMD traits, corresponding to an excess of significant and probably true associations ( Fig. 1) . Exclusion of all SNPs within 500 kb of the SNPs associated at a GWS level and correction for overall meta-analysis genomic control still left many more SNPs associated with BMD than would be expected by chance alone. This indicates that, among many false positives appearing at less stringent statistical thresholds, additional truly associated BMD variants might exist.
The meta-analysis identified 467 SNPs from 20 genomic loci exceeding the GWS threshold of association with the BMD traits ( Fig. 2) . Of these, 15 loci associated with LS-BMD ( Supplementary Tables 4a and 5a) and  10 with FN-BMD (Supplementary Tables 4b  and 5b ); 5 of these loci were associated with both skeletal sites. The effect sizes and significance of the top SNPs from the 20 regions that contained markers associated with LS-BMD and FN-BMD at GWS are shown in Table 1 . Applying correction for overall metaanalysis genomic control resulted in 7 of the 20 loci not reaching GWS (with 7.1 × 10 −7 > P > 5.0 × 10 −8 ). For most markers, heterogeneity was not very large or statistically significant.
Despite the correlation between LS-BMD and FN-BMD measurements, we found site-specific effects. Seven of the 20 loci showed evidence for skeletal site specificity (P < 0.05), and among these 3 showed strong evidence for site specificity (P < 1 × 10 −6 ). This site specificity is to be expected given the differences in heritability and the fact that the genetic correlation (or fraction of 'shared' heritability) between the measurements is considerably less than 1 ( Supplementary Table 6 ).
Genes in associated regions and their functions
Of the 20 BMD loci identified in this scan at a GWS level, 7 have been reported previously as GWS 12, 13, 24 , whereas the remaining 13 have not. Of these 13 loci not previously associated with BMD at a GWS level, 4 were suggestively associated in previous reports 12, 13 and 9 are loci not previously reported to be associated with BMD. In Supplementary  Table 7 , we present a summary of relevant gene annotations including related pathways, monogenic syndromes, knockout mouse models and additional functional details of the genes that are most likely to underlie the associated signals at these 13 loci.
New loci associated with BMD at GWS level
We identified nine previously unreported loci that showed associations with BMD, for which we present Forest plots of effects ( Fig. 3) and regional association plots ( Supplementary Fig. 1 ) for the top SNPs.
1p31.3 (GRP177). Two common SNPs (minor allele frequency (MAF) = 0.21) in complete pairwise linkage disequilibrium (LD) (rs1430742 and rs2566755) were associated at a GWS level with both FN-BMD and LS-BMD. Both top SNPs are located within an intron of the GPR177 (G protein-coupled receptor 177, also called WNTLESS homolog) gene. GPR177 is part of the highly evolutionarily conserved Wnt signaling pathway 25 , which is involved in bone cell differentiation and development. The gene is a positive regulator of the I-κB kinase-NF-κB cascade, part of the RANK system. Cross-talk between the NF-κB and mitogen-activated protein kinase (MAPK) pathways has been indicated by the identification of genes that are expressed in both pathways, including several G protein-coupled receptors 26 .
3p22 (CTNNB1). rs87939 (MAF = 0.45), located 103 kb upstream of the CTNNB1 gene on chromosome 3, was associated at a GWS level with FN-BMD. CTNNB1 encodes β-catenin, which is integral to the Wnt signaling pathway and as such is an excellent candidate for BMD regulation, considering that Wnt signaling controls the process of bone resorption by negatively regulating TNFRSF11B expression in osteoblasts 27 .
5q14 (MEF2C). The rs1366594 top SNP (MAF = 0.45), with another 60 GWS markers at this locus, showed skeletal site specificity, being associated with FN-BMD only. The SNP is 197 kb upstream of the MEF2C (MADS box transcription enhancer factor 2, polypeptide C) gene with no other known annotation within the large LD block. MEF2C is a transcription factor that is highly expressed in muscle and allows transcriptional cross-talk between the Ca 2+ /calmodulin-dependent kinase (CaMK) and mitogen-activated protein kinase (MAPK) signaling pathways by signal-dependent dissociation from histone deacetylases (HDACs). MEF2C interacts with HDAC4 and HDAC5 (see 17q21 region below), resulting in repression of the transcriptional activity of MEF2C. In mice, selective degradation of HDACs by the proteasome allows MEF2C to activate the slow myofiber gene program, resulting in enhanced endurance during physical exercise 28 .
7p14-p13 (STARD3NL). rs1524058 (MAF = 0.40), located 81 kb upstream of the STARD3NL (STARD3 N-terminal like) gene (which encodes a cholesterol endosomal transporter), was associated at a GWS level with LS-BMD but less strongly with FN-BMD. A recent study of Asian individuals 29 identified a SNP (rs1721400) in this 7p14 A r t i c l e s region that was associated with BMD measurements of the radius, tibia and heel (lowest P = 1.4 × 10 −7 ). However, the rs1721400 SNP was not associated with either LS-BMD or FN-BMD in our study (P > 0.05). rs1721400 (mapping close to SFRP4; secreted frizzled-related protein 4) is in very low LD with our top SNP rs1524058 in HapMap individuals of European descent (r 2 = 0.015, D′ = 0.194), whereas LD between markers is considerably higher in Chinese or Japanese individuals (r 2 = 0.230, D′ = 0.931). Thus, an underlying signal common to both Europeans and Asians might still be captured by these SNPs, considering the differences in LD across populations.
7q21.3 (FLJ42280)
. Several SNPs are GWS in this region, with the two top SNPs being in moderate pairwise LD (r 2 = 0.36; D′ = 0.84) and associated at GWS with both LS-BMD and FN-BMD. The SNPs are located within (rs4729260) and just upstream (rs7781370) of FLJ42280, of unknown function. There are several genes within the ~480-kb LD region, of which SHFM1 (split hand/foot malformation (ectrodactyly) type 1) is the closest gene (87-185 kb away).
11p15 (SOX6). rs7117858 (MAF = 0.20) was associated at GWS level with FN-BMD only, displaying strong evidence for skeletal site specificity. The SNP is located 297 kb upstream of the SOX6 (SRY (sex determining region Y)-box 6) gene, which encodes a SOX family transcription factor defined by a conserved high-mobility group DNA-binding domain. The gene is expressed in various tissues, most abundantly in skeletal muscle. Sox6 knockout mice show early lethality due to cardiac insufficiency and present with mild skeletal abnormalities that affect the size and mineralization of endochondral elements 30 . Other SOX-family proteins regulate RUNX2-mediated differentiation of mesenchymal cells during endochondral ossification (skeletogenesis) 31 . 33 , whereas FOXC2 expression is regulated by bone morphogenetic proteins 34 . Skeletal defects of the spine have been reported in Foxc2 mouse knockout models 35 , and deletions and inactivating mutations affecting the FOX gene cluster can cause severe malformations of the VACTER type in humans, which include vertebral malformations 36 .
17q12-q22 (CRHR1). rs9303521 (MAF = 0.46) was associated with LS-BMD and is located 56 kb from the CRHR1 (corticotrophinreleasing factor receptor) gene. Among other genes in this LD region, MAP3K14 is a candidate that could be involved in bone-active pathways, particularly through the activation of NF-κB.
Suggestive loci now associated with BMD at GWS level
Four BMD loci for which this is the first demonstration of a GWS level of association were suggestively associated with BMD in previous reports 12, 13 . We present Forest plots of effects ( Fig. 4) and regional association plots (Supplementary Fig. 2 ) for these SNPs. 2p21 (SPTBN1). rs11898505 (MAF = 0.34), located in an intron of SPTBN1 (spectrin, beta, non-erythrocytic 1), which encodes a major cytoskeletal scaffolding protein, was associated with LS-BMD. The same SNP was previously shown to be associated with BMD and fractures, even though it did not reach GWS level for BMD in the same study 13 . In mice, disruption of β-spectrin isoforms (Elf) leads to the disruption of TGF-β signaling by Smad proteins 37 .
4q21.1 (MEPE). The 4q21.1 region contains a cluster of structurally and phylogenetically related genes that encode matricellular phosphoglycoproteins with functions in bone formation and growth 38 . The top associated rs1471403 SNP (MAF = 0.34) is located 7 kb 3′ of MEPE (matrix, extracellular, phosphoglycoprotein; also known as osteoblast/osteocyte factor 45), 42 kb 3′ of IBSP (integrin-binding sialoprotein) and 122 kb 5′ of SPP1 (secreted phosphoprotein 1, also known as osteopontin). IBSP and SPP1 are highly expressed in osteoblasts, osteoclasts and hypertrophic chondrocytes. MEPE is predominantly expressed by osteocytes in human bone, and inhibits bone formation. Mouse knockout models of these genes show diverse skeletal phenotypes. Mepe (Of45) knockout mice show increased bone mass and inhibition of age-related bone loss 39 ; Ibsp knockout mice show high trabecular bone density with low bone turnover but respond to bone loss caused by disuse 40 ; and Spp1 knockout mice have high trabecular bone mass and are resistant to bone loss 41 . Previously, a nonsynonymous SNP in IBSP (rs1054627, G195E) in moderate LD with rs1471403 (r 2 = 0.2, D′ = 0.8) was reported as being suggestively associated with hip BMD 12 . ARHGAP1; LRP4) . At 11p11.2, a large LD block extends through a region that encompasses several genes, including C11orf49, LRP4, CKAP5, F2 and ARHGAP1. Two fully correlated SNPs (r 2 = 1; MAF = 0.29) -rs7932354, which lies in the promoter region of ARHGAP1 (Rho GTPase activating protein 1), and rs2070852, located in intron 5 of F2 (coagulation factor II) -were associated with FN-BMD at GWS level. Other correlated SNPs in the region (r 2 = 0.2-0.8) were previously suggestively associated with hip BMD and attributed to LRP4 (low-density lipoprotein receptor-related protein 4) 13 . ARHGAP1, a ubiquitous GTPase-activating protein that represses RhoA, is another good candidate. RhoA is a small G protein of the Rho family that regulates cell morphology by actin-cytoskeleton reorganization, which is thought to be a potential commitment switch in the differentiation of mesenchymal stem cells to osteoblasts 42 . In addition, Arhgap1 knockout mouse models show a marked skeletal phenotype, including a threefold reduction in BMD, decreased cortical thickness and bone fragility in older animals 43 . 17q21 (HDAC5; C17orf53) . The 17q21 region contains more than 30 genes in 1 Mb surrounding the top rs228769 SNP (MAF = 0.20), which is located 8 kb upstream of HDAC5 (histone deacetylase 5) and 26 kb upstream of C17orf53. A nonsynonymous SNP in C17orf53, rs227584 (T126P), which is moderately correlated with rs228769 (r 2 = 0.64), was found to be associated with hip BMD, albeit not at GWS level 12 . These SNPs probably represent the same signal. HDAC5 encodes a class II histone deacetylase (homologous to yeast Hda1) that is ubiquitously expressed and responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone acetylation and deacetylation are important in transcriptional regulation, cell cycle progression and developmental events, particularly for myocyte differentiation 44 . In undifferentiated myoblasts, HDAC5 is present in the nucleus where it binds to the myocyte enhancer MEF2C (see above) to repress transcription and inhibit muscle maturation. In bone, recruitment of class II histone deacytylases such as HDAC5 is needed for TGF-β mediated osteoblast differentiation 45 , which occurs through inhibition of Runx2 function by Smad3 (ref. 46 ).
11p11.2 (
Known loci associated with BMD at GWS level
We have replicated at GWS level seven loci that were associated with BMD in previous GWAS 12, 13, 24 : 1p36 (ZBTB40), 6q25 (ESR1), 8q24 (TNFRSF11B, which encodes Opg), 11q13.4 (LRP5), 12q13 (SP7, which encodes osterix, or OSX), 13q14 (TNFSF11, which encodes RANKL) and 18q21 (TNFRSF11A, which encodes RANK). Regional association plots for all seven regions are included in Supplementary  Figure 3 . In the 6q25 (ESR1) region, at least two independent GWS signals are seen on either side of a high-recombination-rate peak (Supplementary Fig. 3b ). This locus showed a complex pattern of association in a previous study, indicating three independent signals at the locus 13 . In Supplementary Table 8 , we report the associations observed in this study for all loci reported previously as attaining GWS or suggestive association 12, 13, 24 . SNPs from the 6p21.32 (MHC locus), 14q32 (MARK3) and 17q21 (SOST) regions described previously to be GWS 13 were still significantly associated with BMD in our study, but not at a GWS level. Note that in the previous study the 14q32 and the 17q21 regions were associated with total hip BMD, which differs from the femoral neck BMD phenotype used in the current study.
Gene expression quantitative trait locus (eQTL) associations
We tested the association of SNPs (or proxies) from the 13 newly GWS associated regions with cis-allelic expression of gene transcripts in primary human osteoblasts. All SNPs associated with gene expression at P < 0.05 and located in the same LD block as the strongest associated variants (D′ ≥ 0.8) are shown in Supplementary Table 9 .
Associations were seen for transcripts of GPR177, MEF2C and FOXC2. Similarly, for variants in (or in LD with variants in) MEPE, the most significant correlation with expression in osteoblasts was seen with IBSP, whereas MEPE seems not to be highly expressed in osteoblasts. However, the statistical evidence is not fully conclusive as only subtle over-representation of the associated loci was observed (10.5% versus 7% for nonassociated control SNPs, χ 2 = 8.9 and P = 0.003). The small over-representation of the associated loci indicates that several of the associated genes might be expressed in cells and tissues other than those from osteoblast lineages.
Combined effect of the 20 GWS BMD loci and fracture risk
We examined the combined effect of the top SNPs arising from the 20 associated BMD loci in 4,983 individuals from the prospective population-based Rotterdam Study. Risk allele counts were derived from the top associated SNPs from the 15 LS-BMD and 10 FN-BMD loci, all of which showed a normal frequency distribution in the study population (Fig. 5) . The 15 LS-SNPs combined explained In contrast, the compound LS-BMD allelic score was significantly associated with the risk of vertebral fracture (OR = 1.061, 95% CI [1.009, 1.116]; P = 0.02), whereas it was not significant for association with the risk of incident nonvertebral fracture (HR = 1.025, 95% CI [0.993, 1.058]; P = 0.13). Adjustment for BMD showed that at least 54% of the genetic effect on incident nonvertebral fracture could be explained by FN-BMD (HR adjusted = 1.019, 95% CI [0.980,1.060]; P = 0.35), whereas 78% of the genetic effect on vertebral fracture was through LS-BMD (OR adjusted = 1.013, 95 %CI [0.962,1.068]; P = 0.62). Despite power limitations, consistent significant associations between the compound BMD allelic scores were observed with the risk of both vertebral and nonvertebral fracture.
DISCUSSION
The GEFOS Consortium has been assembled to identify the genetic determinants of osteoporosis and fracture. This study represents the first step in a collaborative effort and expands our knowledge of the underlying genetics of BMD, a clinical measurement used for the diagnosis of osteoporosis and the assessment of fracture risk. BMD measures of the lumbar spine and femoral neck were analyzed independently because, despite a relatively high phenotypic correlation, the genetic correlation is not perfect. This is illustrated by the site specificity detected in some of the associations, probably reflecting genuine biological mechanisms (differences in cortical versus trabecular bone content), but also intrinsic measurement differences (artifacts influencing BMD values, such as osteophytes of the lumbar spine or aortic calcifications).
Performing meta-analysis of GWAS has limitations. False positive associations might be generated from multiple hypothesis testing and population stratification. Nevertheless, we applied established methods to minimize the impact of multiple testing by applying stringent GWS thresholds to determine significance. Also, our findings are constrained by the power of our current sample, suited to identify effect sizes explaining ~0.2% of the variance of the trait. Further, we are not powered to detect real effects of the same (small) magnitude arising within specific sex and/or age groups. Similarly, owing to power limitations, we cannot address potential gene-gene and gene-environment interactions or the effects of rare alleles that are not captured by the SNP panels screened in GWAS, nor can we determine the effect on fracture risk. Despite the study's being underpowered to assess heterogeneity of effects, some markers showed significant heterogeneity and were not GWS when analyzed under the random effects model. Further evaluation of such markers in larger populations is needed to determine the source(s) of heterogeneity across datasets, which may include inaccuracies in the imputations, subtle differences in phenotype ascertainment, differences in linkage to the causal variant, differences in environmental modifying factors, or genuinely different genetic effects between populations 47 . Achieving such a sufficiently powered setting is the target of the expanding GEFOS Consortium.
All our most highly associated markers showed high-quality imputation scores, high correlation after de novo genotyping and/or at least one genotyped proxy in complete LD that was also associated at GWS level ( Supplementary Table 10 ). Thus, we can exclude imputation inaccuracies as a major source of heterogeneity and/or false-positive associations. In addition, we excluded individuals with non-European profiles, which confines our current findings to the context of populations of Northern European descent. Similarly, test statistics corrected by the genomic inflation factors that affected each study makes it unlikely that population stratification or relatedness (like those observed in the ERF, TUK and dCG populations) are important in our associations. In addition, we examined the effect of applying a second correction for overall meta-analysis genomic control in our results. Only one locus (LRP5) was substantially below the GWS threshold after correction. This is remarkable considering that the association of variants in LRP5 has been consistently replicated at GWS level in at least two previous efforts 10, 24 .
In summary, we identified and/or confirmed at least 20 loci associated with lumbar spine and femoral neck BMD, highlighting the complex genetic architecture that underlies the variation in BMD. However, these loci explain only a small fraction of the variance in BMD and hence an even smaller fraction of the heritability for fracture risk. Nevertheless, these findings highlight molecules within new and known biological pathways that influence BMD variation, particularly the Wnt and NF-κB signaling pathways (including about half of the identified loci: GPR177, CTNNB1, FOXC2, LRP5, SPTBN1, HDAC5, TNFSF11, TNFRSF11A and TNFRSF11B). None of the SNPs we have identified can be unequivocally designated as the underlying 'true' variants driving the associations. Additional efforts to identify such variants are warranted to maximize the application of this genetic knowledge to the prediction of risk in individuals and the translation into new pharmacological agents for treating osteoporosis. Increasing the sample size further will aid the identification of additional loci associated not only with BMD but also with risk of fracture, the ultimate consequence of osteoporosis. 
A r t i c l e s
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession numbers. OMIM 48, 49 : GPR177 (611514); CTNNB1 (116806); MEF2C (600662); STARD3NL (611759); FLJ42280 (none); SHFM1 (183600); SOX6 (607257); DCDC5 (612321); DCDC1 (608062); FOXC2 (602402); FOXL1 (603252); CRHR1 (http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=122561); SPTBN1 (182790); MEPE (605912); IBSP (147563); SPP1 (166490); ARHGAP1 (602732); LRP4 (604270); F2 (176930); HDAC5 (605315); C17orf53 (none); ZBTB40 (612106); ESR1 (133430); C6orf97 (none); TNFRSF11B (602343); LRP5 (603506); SP7 (606633); TNFSF11 (602642); AKAP11 (604696); TNFRSF11A (603499). 50, 51 . The Erasmus Rucphen Family study is a family-based study of a genetic isolate in the southwest Netherlands to identify genetic risk factors for complex disorders 52 . The Twins UK study is a population-based sample of twins from the UK studying the hereditary basis of a variety of age-related traits and diseases (http://www.twinsUK.ac.uk) 53 . The Icelandic deCODE Genetics study uses a population-based sample to identify the genetic basis of complex diseases 13 Phenotype modeling. The overall strategy involved linear regression to adjust BMD measurements for effects of age, weight, sex and study using standardized residuals with mean 0 and s.d. 1 in the genotype-phenotype association testing. Such residuals were obtained by regressing within each study the raw BMD measurements on age and weight (and principal components in FOS to adjust for population substructure using EIGENSTRAT 57 ) in sex-specific models. Thus, in studies including both men and women, the data for each gender are included as separate estimates in the meta-analysis. Supplementary  Table 3 . We performed technical validation of the imputed genotypes in an independent set of 880 individuals of Icelandic origin using Centaurus (Nanogen) 61 discrimination assays for the top associated hits that reached GWS for the first time in this study ( Supplementary Table 10 ).
ONLINE METhODS
Genotype-phenotype association testing. Each study performed genomewide association for BMD using sex-specific, age-and weight-adjusted standardized residuals analyzed under an additive (per allele) genetic model 62 Table 3 ). The genomic control method 20 was used to correct the standard error by the square root of the genomic inflation factor (lambda): SE corrected = s.e.m. √λ, which is equivalent to the proposed correction of the χ 2 statistic by lambda. Genomic inflation factors for the studies are presented in Supplementary Table 3 . Overall meta-analysis genomic control inflation factors were calculated as described 67 . Genomic inflation factors scaled to a standard size (1,000 individuals) to calibrate for the effect of sample size on λ 67 showed that residual genomic inflation was negligible (λ LSBMD1000 = 1.005 and λ FN-BMD1000 = 1.004).
Meta-analysis. The minor allele from HapMap CEU genotypes was used to define the coded allele in all analyses, regardless of frequency in individual cohorts. All meta-analysis calculations were done using the METAL 21 software package applying inverse-variance methodology assuming fixed effects with Cochran's Q and I 2 metrics used to quantify between-study heterogeneity. We also calculated the summary results by random effects using STATA software 68 for those markers associated at GWS level with Cochran's Q P value <0.05 and/or I 2 estimates >50%, reflecting large heterogeneity beyond chance. Random effects models also incorporate in the calculations the between-study heterogeneity and estimate the average genetic effect from the population of genetic effects that may differ in different studies. In the absence of betweenstudy heterogeneity, fixed and random effects calculations give identical results. We declared results GWS at α = 5 × 10 −8 after adjusting for all common variant tests in the human genome 22, 23 SNPs included on the Illumina 550K chip were assessed for expression cis associations directly. In addition, all genotyped SNPs included on the Illumina chip that were in strong LD (defined as D′ ≥ 0.8) and mapping ± 50 kb from the GWS hit were included in the association study. To test for significant enrichment of functional SNPs (those associated with gene expression in human osteoblasts at P < 0.05) among the candidate SNPs, a χ 2 statistic was obtained to test whether observed associations were different from expected associations in the expression dataset beyond chance. Expected values (7.1%) were based on the proportion of SNPs with P < 0.05 seen in the human osteoblast gene expression dataset and in a random selection of 1,200 SNPs associated with both LS-BMD and FN-BMD at P > 0.90, MAF > 0.20, and present in the Illumina HumanHap550 array (assessed as negative controls for association with human osteoblast expression).
Combined effect of associated loci. Within the setting of the prospective population-based Rotterdam Study, the combined effect of all 20 BMD loci was studied by classifying subjects according to the number of BMD-decreasing (risk) alleles. This was based on 15 lumbar spine and 10 femoral neck BMD loci as follows. Lumbar spine (15 SNPs): rs7524102 (ZBTB40), rs1430742 (GPR177), rs11898505 (SPTBN1), rs1471403 (MEPE), rs2504063 (ESR1), rs1524058 (STARD3NL), rs4729260 (FLJ42280), rs2062377 (TNFRSF11B), rs16921914 (DCDC5), rs599083 (LRP5), rs2016266 (SP7), rs9533090 (TNFSF11), rs10048146 (FOXC2), rs9303521 (CRHR1) and rs884205 (TNFRSF11A). Femoral neck (10 SNPs): rs6426749 (ZBTB40), rs2566755 (GPR177), rs87938 (CTNNB1), rs1366594 (MEF2C), rs2941740 (ESR1), rs7781370 (FLJ42280), rs11995824 (TNFRSF11B), rs7117858 (SOX6), rs7932354 (ARHGAP1) and rs228769 (HDAC5)). The mean BMD for each risk allele-count group was determined, and at the extremes of the distribution counts were pooled into the nearest risk allele-count group of >100 individuals. The approximate BMD difference in g/cm 2 was obtained by multiplying in each group the mean Z-score LS-BMD by 0.18 g/cm 2 and the mean Z-score FN-BMD by 0.13 g/cm 2 (the s.d. values for BMD in the Rotterdam Study). The allele score was obtained by dividing the number of 'BMD-decreasing alleles' by the total number of alleles. Also within the setting of the prospective population-based Rotterdam Study, we determined the risk for vertebral and nonvertebral fracture for the combined allelic scores constructed for all the top hits associated at a GWS level with BMD. Risk ratio (RR) estimates were obtained from logistic regression (vertebral fractures) and Cox-proportional hazards (incident nonvertebral fractures) models adjusted for sex, age and weight. To determine the fraction of fracture risk explained by BMD, we applied the following formula: [lnRR unadjusted − lnRR BMDadjusted ]/lnRR unadjusted . Methods describing the fracture datasets have been published 71, 72 . In summary, thoracolumbar radiographs of the spine were obtained in 3,308 (genotyped) individuals who survived on average 6.4 ± 0.4 (s.d.) years and were scored for presence of vertebral fractures (n = 329) using the McCloskey/Kanis method 73 . Record of the incidental nonvertebral fractures (n = 900) occurring between the baseline visit from 1990 through 1993 until 1 January 2002, was obtained from the computerized records of general practitioners and hospital registries for 5,974 genotyped individuals followed on average 8.2 ± 2.7 (s.d.) years after the baseline visit.
